- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01372306
Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the studyI unless otherwise specified:
- Healthy adult male volunteers, 18-55 years of age;
- Weighing at least 60 kg and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Ufe Insurance Company, 1983);
- Medically healthy subjects with clinically normal laboratory profiles, vital signs and ECGs;
- Give voluntary written informed consent to participate in the study.
Exclusion Criteria:
Subject candidates must not be enrolled in the stUdy if they meet any of the following criteria:
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
- In addition, history or presence of:
- alcoholism or drug abuse within the past year;
- hypersensitivity or idiosyncratic reaction to galantamine or other anticholinesterase inhibitors;
- asthma and seizures.
- Subjects who tested positive at screening for HIV, HbsAg or HCV.
- Subjects whose PR interval is >200 msec at screening and prior to dosing.
- Subjects whose QTc interval is >450 msec at screening and prior to dosing.
- Subjects who have used any drugs or substances known to be strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
- Subjects who have used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
- Subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.
Subjects who, through completion of the stUdy, would have donated in excess of:
500 mL of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year.
- Subjects who have participated in another clinical trial within 28 days prior to the first dose.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Galantamine
Galantamine Hydrobromide Tablets of Dr. Reddy's
|
Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Other Names:
|
Active Comparator: Reminyl
Reminyl 4 mg tablets of Janssen Pharmaceutical Products
|
Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence on Cmax and AUC parameters
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gaerano Morelli, Early Clinical Research
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AA21897
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Umeå UniversityUniversity of California; Mead Johnson NutritionActive, not recruitingHealth of Formula-fed Children | Infant Infections in Formula-fed Children | Iron Status of Formula-fed ChildrenSweden
-
Dr. Reddy's Laboratories LimitedCompleted
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
Clinical Trials on Reminyl
-
Dr. Reddy's Laboratories LimitedCompleted
-
Ludwig-Maximilians - University of MunichUnknownAlzheimer's DiseaseGermany
-
Janssen Korea, Ltd., KoreaCompleted
-
Janssen-Cilag Pty LtdCompletedDementia | Alzheimer Disease | GalantamineAustralia
-
University Hospital, BonnFederal Ministry of Health, GermanyUnknown
-
Seattle Institute for Biomedical and Clinical ResearchTerminated
-
University of Sao PauloUniversity of Nove de Julho; Feinstein Institute for Medical ResearchCompletedAbdominal Obesity Metabolic SyndromeBrazil
-
Samsung Medical CenterJanssen Korea, Ltd., KoreaCompleted
-
University of North Carolina, Chapel HillOrtho-McNeil Neurologics, Inc.CompletedStroke | Aphasia
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed